Onyx Biotec Ltd (ONYX) — shareholding pattern, promoter holding, financials and share price
About Onyx Biotec Ltd (ONYX)
Onyx Biotec Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ONYX and on the BSE under scrip code 93585. Its ISIN is INE0WVU01018.
Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas, through a B2B business model [1]
Onyx Biotec Limited, founded in 2005, is a pharmaceutical manufacturer specializing in sterile water for injections, dry powder injections, and dry syrup, catering to both Indian and global markets.
The company boasts robust manufacturing capabilities with two manufacturing units in Solan, Himachal Pradesh, offering a combined capacity of over 230 million units annually.
Listed peers in Pharmaceuticals: Bharat Immunological & Biological Corporation Ltd, Sunil Healthcare Ltd, Source Natural Foods & Herbal Supplements Ltd, Vilin Bio Med Ltd, Phaarmasia Ltd, Asston Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹38.6 a share on 10 Jul 2026, Onyx Biotec Ltd (ONYX) was valued at a price-to-earnings ratio of -333.29x against an industry P/E of 36.41x and a price-to-book of 1.26x on a book value of ₹30.56 per share. Solomo computes return on equity of -0.39% and return on capital employed of 1.12% from filed results.
- P/E
- -333.29x
- Industry P/E
- 36.41x
- P/B
- 1.26x
- EPS (TTM)
- ₹3.31
- Book value / share
- ₹30.56
- ROE
- -0.39%
- ROCE
- 1.12%
- ROA
- -0.22%
- Debt / equity
- 0.27x
- Dividend yield
- 0%
- EBITDA margin
- 5.53%
- 52-week range
- ₹24.2 – ₹53.9
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Onyx Biotec Ltd (ONYX) reported revenue of ₹69.47 crore, net profit of ₹-0.21 crore and earnings per share of ₹-0.12. That compares with revenue of ₹61.95 crore and net profit of ₹4.95 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹34.88 crore and net profit ₹0.69 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 44.86 | 39.49 | 53.75 | 61.95 | 69.47 |
| Net profit (₹ cr) | 3.35 | 1.84 | 3.63 | 4.95 | -0.21 |
| EPS (₹) | 5.68 | 3.12 | 2.72 | 2.73 | -0.12 |
| Measure | 3Y | 1Y |
|---|---|---|
| Sales growth | 11.36% | 15.26% |
| Profit growth | 13.90% | 36.36% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 65.1% of Onyx Biotec Ltd (ONYX). Market capitalisation was ₹70 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2025.
Largest disclosed public shareholders in Mar 2026: INVICTA CONTINUUM FUND I 2.39%, APNEET KAHLON 1.65%, PROGNOSIS SECURITIES PRIVATE LIMITED 1.52%, INVICTA CAPSERV 1.52%, KADAYAM RAMANATHAN BHARAT 1.1%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 65.1% | - | - | - | - |
| Sep 2025 | 65.1% | - | - | - | - |
| Mar 2025 | 65.1% | - | - | - | - |